Skip to main content

Table 1 Comparison of variables with 12-chemokine gene signature

From: Evaluation of invasive breast cancer samples using a 12-chemokine gene expression score: correlation with clinical outcomes

   N (%)  
Variable Level Total Low 12-chemokine High 12-chemokine p value
Race White 331 (90.4%) 159 (86.9%) 172 (94%) 0.03
Not white 35 (9.6%) 24 (13.1%) 11 (6%)
Histology Ductal 284 (77.6%) 136 (74.3%) 148 (80.9%) 0.371
Lobular 52 (14.2%) 30 (16.4%) 22 (12%)
Others 30 (8.2%) 17 (9.3%) 13 (7.1%)
Tumor grade Well differentiated 36 (10.1%) 26 (14.9%) 10 (5.6%) <0.0001
Moderately differentiated 148 (41.7%) 90 (51.4%) 58 (32.2%)
Poorly/undifferentiated 171 (48.2%) 59 (33.7%) 112 (62.2%)
Cancer status Free (NED) 274 (82.5%) 138 (83.6%) 136 (81.4%) 0.668
Not free of tumor 58 (17.5%) 27 (16.4%) 31 (18.6%)
TNM stage 1 95 (27.9%) 49 (29.2%) 46 (26.7%) 0.709
2 176 (51.8%) 83 (49.4%) 93 (54.1%)
3 69 (20.3%) 36 (21.4%) 33 (19.2%)
Any adjuvant treatment No 49 (13.5%) 23 (12.7%) 26 (14.3%) 0.755
Yes 314 (86.5%) 158 (87.3%) 156 (85.7%)
Receptor status (ER+ or PR+)/(HER2- or HER2 missing) 212 (63.5%) 121 (72.9%) 91 (54.2%) 0.001
ER-/PR-/(HER2- or missing) 67 (20.1%) 26 (15.7%) 41 (24.4%)
HER2+ 55 (16.5%) 19 (11.4%) 36 (21.4%)
Survival status Alive 263 (71.9%) 133 (72.7%) 130 (71%) 0.82
Dead 103 (28.1%) 50 (27.3%) 53 (29%)
Recurrence status No recurrence 272 (76.6%) 130 (73%) 142 (80.2%) 0.133
Recurrence 83 (23.4%) 48 (27%) 35 (19.8%)
  1. NED no evidence of disease, ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2
  2. A higher chemokine score was associated with Caucasian race, higher grade, ER- status, and HER2+ status